Neurotune expands its management by taking on an expert for preclinical development and appointing a new CFO

Schlieren, 1st August 2007. Neurotune AG has taken on Dr. Jan Willem Vrijbloed for the expansion of its preclinical development division, and has appointed Michael Kregar as the new Chief Financial Officer (CFO).
As the director of preclinical and clinical development, Dr. Jan Willem Vrijbloed will be responsible for the development of new medications. Dr Vrijbloed, was born in 1960 in the Netherlands and has more than 15 years of experience in preclinical and clinical development, as well as exploration of new substances in the field of cancer medication and antibiotics, plus research in organic chemistry and microbiology. Dr Vrijbloed acquired his diploma in biology and later his doctorate at the University of Groningen. After working at the University of Zurich and collaborating with Akzo-Nobel, Dr Vrijbloed joined Polyphor Ltd. in Switzerland in 2000, where he was initially Head of Biology and later Head of Development.
Michael Kregar was appointed Neurotune’s new CFO on July 1, 2007. He succeeds interim manager Bruno Odermatt, who will now be able to concentrate fully on his job as CFO at Prionics AG.
Michael Kregar, was born in 1970 in Switzerland, and is an expert with more than 15 years of experience as a manager of financial planning, controlling and revision, which he gained from different companies. His last post was as European Controller & Head of Finance in the Finance division of the Biolife Business Unit at Baxter Healthcare SA. He has also worked for Energis Carrier Services, PricewaterhouseCoopers und AT&T Corp in the UK and the US. Mr Kregar, is a certified public accountant in North Dakota, holds a Master of Business Administration from the Purdue University Krannert School of Management, and is currently completing his doctorate at the Manchester Business School of Manchester University in England.

Photos available on request.

Contact:
Mrs. Theres Oesch
Assistant to the CEO
neurotune ag
Wagistrasse 27
8952 Schlieren (Zurich)
Switzerland
URL www.neurotune.com
Phone +41 44 200 21 95
Fax +41 44 200 20 10
theres.oesch@neurotune.com

Media enquiries
Dr. Holger Bengs
Biotech Consulting
Phone +49 (0)69 6199 4273
Fax: +49 (0)69 6199 4249

info@holgerbengs.de

About Neurotune AG
Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has its seat in Schlieren (Zurich), Switzerland.
Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy - Sarcopenia, second priority to drugs for rehabilitation therapies after stroke or traumatic brain injury, and third priority is given to drugs for treatment of other CNS disturbances.

About Sarcopenia
With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy –Sarcopenia - is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.
The treatment of Sarcopenia is a growing market with no available causal treatment.

* * * * *

This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the Neurotunes' shelf registration statement and the registered direct offering. For further information regarding these and other risks related to Neurotunes’ business, investors should consult Neurotune.

This release was published on openPR.